Infratil - 1H25 Result — A Waiting Game
Investors are on a knife edge, awaiting the catalyst with a capital C — a transactional third-party validation of CDC's valuation. It is hard to...
338 Views
Infratil - 1H25 Preview — Contracts and Competition
We approach Infratil (IFT) 1H25 result on Thursday, 14 November with a heightened degree of uncertainty. IFT's largest EBITDAF contributor is One NZ.
210 Views
Infratil - Coming up for Air — Down to NEUTRAL
Investors in Infratil (IFT) have been richly rewarded over the last three decades, with total returns of almost +20% annually, or ~270x your money.
346 Views
Infratil - De-Risking CDC's Breakneck Growth
CDC now makes up nearly half of IFT's total asset value. We reiterate our OUTPERFORM rating with an increased target price of NZ$13.00.
164 Views
Infratil Placement - Riding the AI Wave, but Deal Timing Seems Opportunistic
Infratil Ltd (IFT NZ) aims to raise around US$613m (NZ$1bn) via an institutional placement. In this note, we talk about the deal dynamics and run...
129 Views